Investment Research and Business Due Diligence
Thursday, July 18, 2013
Merck and Lupin collaborate to co-market Merck's 23 Valent Pneumococcal polysacharide vaccine for Indian market
Merck has partnered with India based Lupin to co-market its pnemococcal vaccine in India. Lupin gets a non-exclusive license to market, promote and distribute Pneumovax under a different brand name in India. With patients suffering from respiratory disease like Asthma as candidates for pneumococcal vaccination, Lupin which has a strong presence in this segment seems to be a right choice.
The Pneumococcal vaccine is sold under the brand name Pneumovax 23 in the US. It is indicated for indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1,2,3,4,5, 6B, 7F,8,9N,9V, 10A, 11A,12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F,and 33F). PNEUMOVAX 23 is approved for usein persons 50 years of age or older and persons aged ≥2 years who areat increased risk forpneumococcal disease.
Recent India focused study showed that more than 80% of invasive serotype groups of
Streptococcus pneumoniae causing disease in the elderly in India are included in the
formulation of PPV 23 which makes this vaccine relevant from India perspective
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)